0001314052 2024-10-01 2025-09-30 0001314052 2025-03-31 0001314052 2025-11-24 0001314052 2025-09-30 0001314052 2024-09-30 0001314052 2023-10-01 2024-09-30 0001314052 2022-10-01 2023-09-30 0001314052 2023-09-30 0001314052 2022-09-30 0001314052 us-gaap:CommonStockMember 2022-09-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001314052 us-gaap:RetainedEarningsMember 2022-09-30 0001314052 us-gaap:CommonStockMember 2023-09-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001314052 us-gaap:RetainedEarningsMember 2023-09-30 0001314052 us-gaap:CommonStockMember 2024-09-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001314052 us-gaap:RetainedEarningsMember 2024-09-30 0001314052 us-gaap:CommonStockMember 2022-10-01 2023-09-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2023-09-30 0001314052 us-gaap:RetainedEarningsMember 2022-10-01 2023-09-30 0001314052 us-gaap:CommonStockMember 2023-10-01 2024-09-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2024-09-30 0001314052 us-gaap:RetainedEarningsMember 2023-10-01 2024-09-30 0001314052 us-gaap:CommonStockMember 2024-10-01 2025-09-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2025-09-30 0001314052 us-gaap:RetainedEarningsMember 2024-10-01 2025-09-30 0001314052 us-gaap:CommonStockMember 2025-09-30 0001314052 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001314052 us-gaap:RetainedEarningsMember 2025-09-30 0001314052 avxl:MichaelJFoxFoundationMember 2024-10-01 2025-09-30 0001314052 2020-10-01 2021-09-30 0001314052 currency:AUD 2024-10-01 2025-09-30 0001314052 currency:AUD 2023-10-01 2024-09-30 0001314052 currency:AUD 2022-10-01 2023-09-30 0001314052 currency:AUD 2025-09-30 0001314052 currency:AUD 2024-09-30 0001314052 avxl:PurchaseAgreement2023Member avxl:LincolnParkCapitalFundLLCMember 2023-02-02 2023-02-03 0001314052 avxl:CommonStockIncludingCommitmentSharesMember avxl:PurchaseAgreement2023Member avxl:LincolnParkCapitalFundLLCMember 2023-10-01 2024-09-30 0001314052 avxl:CommonStockExcludingCommitmentSharesMember avxl:PurchaseAgreement2023Member avxl:LincolnParkCapitalFundLLCMember 2024-10-01 2025-09-30 0001314052 avxl:PurchaseAgreement2023Member avxl:LincolnParkCapitalFundLLCMember 2024-10-01 2025-09-30 0001314052 avxl:CommitmentSharesMember avxl:PurchaseAgreement2023Member avxl:LincolnParkCapitalFundLLCMember 2024-10-01 2025-09-30 0001314052 avxl:CommonStockIncludingCommitmentSharesMember avxl:PurchaseAgreement2023Member avxl:LincolnParkCapitalFundLLCMember 2022-10-01 2023-09-30 0001314052 avxl:CommonStockExcludingCommitmentSharesMember avxl:PurchaseAgreement2023Member avxl:LincolnParkCapitalFundLLCMember 2022-10-01 2023-09-30 0001314052 avxl:PurchaseAgreement2023Member avxl:LincolnParkCapitalFundLLCMember 2022-10-01 2023-09-30 0001314052 avxl:CommitmentSharesMember avxl:PurchaseAgreement2023Member avxl:LincolnParkCapitalFundLLCMember 2022-10-01 2023-09-30 0001314052 srt:ChiefExecutiveOfficerMember 2025-09-30 0001314052 srt:ChiefExecutiveOfficerMember 2024-10-01 2025-09-30 0001314052 srt:DirectorMember 2025-09-30 0001314052 srt:DirectorMember 2024-10-01 2025-09-30 0001314052 avxl:BoardMember 2025-09-30 0001314052 avxl:ChiefExecutiveOfficer1Member 2025-09-30 0001314052 avxl:ChiefExecutiveOfficer1Member 2024-10-01 2025-09-30 0001314052 avxl:ChiefExecutiveOffice1rMember 2024-10-01 2025-09-30 0001314052 avxl:StockOptionPlan2015Member 2025-09-30 0001314052 avxl:StockOptionPlan2019Member 2024-10-01 2025-09-30 0001314052 avxl:StockOptionPlan2022Member 2021-10-01 2022-09-30 0001314052 avxl:StockOptionPlan2022Member 2022-03-24 2022-03-25 0001314052 2025-04-17 0001314052 avxl:StockOptionPlan2022Member 2025-09-30 0001314052 us-gaap:StockOptionMember 2024-09-30 0001314052 us-gaap:StockOptionMember 2024-10-01 2025-09-30 0001314052 us-gaap:StockOptionMember 2025-09-30 0001314052 us-gaap:StockOptionMember avxl:OptionPrice1Member 2024-10-01 2025-09-30 0001314052 us-gaap:StockOptionMember avxl:OptionPrice1Member 2025-09-30 0001314052 us-gaap:StockOptionMember avxl:OptionPrice2Member 2024-10-01 2025-09-30 0001314052 us-gaap:StockOptionMember avxl:OptionPrice2Member 2025-09-30 0001314052 us-gaap:StockOptionMember avxl:OptionPrice3Member 2024-10-01 2025-09-30 0001314052 us-gaap:StockOptionMember avxl:OptionPrice3Member 2025-09-30 0001314052 us-gaap:StockOptionMember avxl:OptionPrice4Member 2024-10-01 2025-09-30 0001314052 us-gaap:StockOptionMember avxl:OptionPrice4Member 2025-09-30 0001314052 us-gaap:StockOptionMember avxl:OptionPrice5Member 2024-10-01 2025-09-30 0001314052 us-gaap:StockOptionMember avxl:OptionPrice5Member 2025-09-30 0001314052 avxl:GeneralAndAdministrativeExpensesMember 2024-10-01 2025-09-30 0001314052 avxl:GeneralAndAdministrativeExpensesMember 2023-10-01 2024-09-30 0001314052 avxl:GeneralAndAdministrativeExpensesMember 2022-10-01 2023-09-30 0001314052 avxl:ResearchAndDevelopmentExpensesMember 2024-10-01 2025-09-30 0001314052 avxl:ResearchAndDevelopmentExpensesMember 2023-10-01 2024-09-30 0001314052 avxl:ResearchAndDevelopmentExpensesMember 2022-10-01 2023-09-30 0001314052 avxl:FederalMember 2025-09-30 0001314052 avxl:FederalMember 2024-09-30 0001314052 avxl:FederalMember 2024-10-01 2025-09-30 0001314052 us-gaap:StateAndLocalJurisdictionMember 2025-09-30 0001314052 us-gaap:StateAndLocalJurisdictionMember 2024-09-30 0001314052 us-gaap:ForeignCountryMember 2025-09-30 0001314052 currency:AUD us-gaap:ForeignCountryMember 2025-09-30 0001314052 us-gaap:ForeignCountryMember 2024-09-30 0001314052 currency:AUD us-gaap:ForeignCountryMember 2024-09-30 0001314052 avxl:PreclinicalStudiesMember 2024-10-01 2025-09-30 0001314052 avxl:PreclinicalStudiesMember 2023-10-01 2024-09-30 0001314052 avxl:PreclinicalStudiesMember 2022-10-01 2023-09-30 0001314052 avxl:ClinicalTrialsMember 2024-10-01 2025-09-30 0001314052 avxl:ClinicalTrialsMember 2023-10-01 2024-09-30 0001314052 avxl:ClinicalTrialsMember 2022-10-01 2023-09-30 0001314052 avxl:PersonnelCostsMember 2024-10-01 2025-09-30 0001314052 avxl:PersonnelCostsMember 2023-10-01 2024-09-30 0001314052 avxl:PersonnelCostsMember 2022-10-01 2023-09-30 0001314052 avxl:NonCashShareBasedCompensationMember 2024-10-01 2025-09-30 0001314052 avxl:NonCashShareBasedCompensationMember 2023-10-01 2024-09-30 0001314052 avxl:NonCashShareBasedCompensationMember 2022-10-01 2023-09-30 0001314052 avxl:OtherResearchAndDevelopmentCostsMember 2024-10-01 2025-09-30 0001314052 avxl:OtherResearchAndDevelopmentCostsMember 2023-10-01 2024-09-30 0001314052 avxl:OtherResearchAndDevelopmentCostsMember 2022-10-01 2023-09-30 iso4217:USD shares iso4217:USD shares pure true FY 0001314052

10-K/A true 2025-09-30 --09-30 2025 false 001-37606 ANAVEX LIFE SCIENCES CORP. NV 98-0608404 630 5th Avenue 20th Floor New York NY US 10111 844 689-3939 Common Stock Par Value $0.001 AVXL NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 708000000 89348107 As previously disclosed in a Current Report on Form 8-K, filed with the Securities and Exchange Commission (“SEC”) on May 6, 2026, on April 30, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors of the Company (the “Board”) terminated the employment of the Company’s former Chief Executive Officer (“CEO”) for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between the Company and its former CEO, as amended and restated), effective immediately for, among other things, conduct that the Special Committee believed was inconsistent with Company policy. As a result of the review by the Special Committee, management, in consultation with the Audit Committee of the Board (the “Audit Committee”), concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025. Accordingly, the Company’s internal control over financial reporting as of September 30, 2025, as reported in its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (the “Original Form 10-K”) was not effective. In addition, the Company’s disclosure controls and procedures were not effective as of September 30, 2025, due to the material weakness in internal control over financial reporting as described above. The reassessment of the effectiveness of the Company’s disclosure controls and procedures and its internal control over financial reporting described above did not result in any misstatement in the Company’s previously issued annual consolidated financial statements for the year ended September 30, 2025, included in the Original Form 10-K. As a result, the Company is not restating its annual consolidated financial statements contained in Item 8 of this Amendment. The Company is filing this Amendment No. 1 (this “Amendment”) to the Original Form 10-K solely to amend the following: ● Item 8. “Financial Statements and Supplementary Data” of the Original Form 10-K is amended and restated to (1) restate Grant Thornton LLP’s opinion on the Company’s internal control over financial reporting and (2) update Grant Thornton LLP’s unqualified opinion on the Company’s consolidated financial statements to refer to its restated opinion on the Company’s internal control over financial reporting; ●Item 9A. “Controls and Procedures” of the Original Form 10-K is amended and restated to reflect the ineffective disclosure controls and procedures and internal control over financial reporting as of September 30, 2025 as a result of the material weakness discussed therein; and ●Item 15. “Exhibits, Financial Statement Schedules” of the Original Form 10-K is amended and restated to reflect the new certifications and consent referenced below. This Amendment also includes the following exhibits to replace exhibits previously filed: ●new currently dated certifications (as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended) , by the Company’s principal executive officer and principal financial officer; and ●a new consent from Grant Thorton LLP. Except as described in this Explanatory Note, this Amendment does not amend, modify or update disclosures included in the Original Form 10-K, nor does it reflect events occurring after the filing of the Original Form 10-K. Among other things, business-related disclosures, risk factors and forward-looking statements made in the Original Form 10-K have not been revised to reflect events that occurred or facts that became known to the Company after the filing of the Original Form 10-K, and any such statements should be read in their historical context. Accordingly, this Amendment should be read in conjunction with the Company’s filings with the SEC that were made subsequent to the filing of the Original Form 10-K and this Amendment. GRANT THORNTON LLP Melville, New York 248

102577000

132187000

809000

2449000

429000

931000

103815000

135567000

4249000

9627000

3892000

4835000

805000

842000

8946000

15304000

10000000

0.001

200000000

0.001

86668521

84795517

87000

85000

477230000

456249000

-382448000

-336071000

94869000

120263000

103815000

135567000

13816000

11039000

12046000

37592000

41838000

43717000

51408000

52877000

55763000

-51408000

-52877000

-55763000

37000 75000 25000 648000 2291000 2718000

4678000

7320000

6519000

964000

-332000

189000

-40000

5031000

9875000

8258000

-46377000

-43002000

-47505000

-0.54

-0.52

-0.60

85289447

83468049

79787596

-46377000

-43002000

-47505000

845000

11549000

9438000

16370000

-1640000

-260000

-484000

-502000

278000

299000

-5378000

5305000

497000

-943000

-2460000

1350000

37000 75000 -473000

-39044000

-30812000

-27785000

9198000 11284000 27875000

2707000

2943000

691000

1776000

9434000

11975000

29651000

-29610000

-18837000

1866000

132187000

151024000

149158000

102577000

132187000

151024000

125000 300000 136000 1493000

77942815

78000

387977000

-245564000

142491000

75000 845000 845000

3275000

3000

27872000

27875000

13943 759753 1000 1775000 1776000

16370000

-47505000

82066511

82000

434839000

-293069000

141852000

2450000

3000

11281000

11284000

5646 273360 691000 691000

9438000

-43002000

84795517

85000

456249000

-336071000

120263000

927910 1000 9197000 9198000 646488 1000 2942000 2943000 737500 1000 1492000 1493000 -438894 -1000 -4199000 -4200000

11549000

-46377000

86668521

87000

477230000

-382448000

94869000

Note 1 Business Description and Basis of Presentation Business Anavex Life Sciences Corp. (“Anavex” or the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high unmet need. Anavex analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The Company’s focus is on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Basis of Presentation These consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and the instructions to Form 10-K and have been prepared under the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain immaterial amounts from prior periods have been reclassified to conform to the current year’s presentation. Liquidity All of the Company’s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues. To date, the Company has not generated any revenue from our operations. The Company expects the business to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, its business might become profitable. Management believes that the current working capital position will be sufficient to meet the Company’s working capital requirements beyond the next 12 months after the date that these consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials are uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company’s expenditures will vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company’s research and development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials. Other than our rights related to the 2025 Sales Agreement and the 2023 Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available when needed or, if available, that it can be obtained on commercially reasonable terms. The Company will need to file a prospectus supplement in order to access funds under the 2023 Purchase Agreement. If the Company is not able to obtain the additional financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.

Note 2 Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Principles of Consolidation These consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (“Anavex Australia”), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have been eliminated. Cash and equivalents The Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts, money market funds and certificates of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company’s investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The Company currently maintains the majority of its investments at one large well known financial institution. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000, under current regulations. At September 30, 2025 and 2024, substantially all of the Company’s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts. Research and Development Expenses Research and development costs are expensed as incurred. These expenses are comprised of the costs of the Company’s proprietary research and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including external research and development expenses incurred under arrangements with third parties such as contract research organizations (“CROs”), facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (“ASC”) 730, Research and Development, as these materials have no alternative future use outside of their intended use. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from actual costs. In addition, the Company incurs expenses in respect of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents and trademarks will ever be successfully commercialized. Due to these risks and uncertainties, the patent and trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses. Research and Development Incentive Income The Company is eligible to obtain certain research and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development tax incentive credit (the “Australia R&D credit”) through a program administered through the Australian Tax Office (the “ATO”) and AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science (“AusIndustry”). The Australia R&D credit program provides for a cash refund based on a percentage of eligible research and development activities undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&D credit program to receive the cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by AusIndustry pursuant to an advanced overseas finding application. The Australia R&D credit program is available to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate of 18.5% above the claimant’s company tax rate in Australia. The tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes (“ASC 740”), since the incentives are not linked to the Company’s taxable income and can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions. With respect to the Australia R&D credit, as there is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant by analogy to IAS20 Accounting for Government Grants and Disclosure of Government Assistance (“IAS 20”). The Company recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&D credit program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry, pursuant to an approved advanced overseas finding application. In addition, Anavex Australia and Anavex Canada incur Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance sheets. License Fees The Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense or capitalized based on management’s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite regulatory approvals are obtained to make the product available for sale. Basic and Diluted Loss per Share Basic income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. As of September 30, 2025, diluted loss per share excludes 14,971,583 potentially dilutive common shares (2024 - 15,047,754; 2023 – 14,271,780) related to outstanding options and warrants, as their effect was anti-dilutive. Financial Instruments The book value of the Company’s financial instruments, consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. Foreign Currency Translation The functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income in the period in which they occur. The Company has determined that the functional currency of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar. Segment and Geographic Reporting The Company determines and presents operating segments based on the information that is internally provided to the Company’s chief operating decision maker (“CODM”), its Chief Executive Officer, in accordance with ASC 280, Segment Reporting. The Company has determined that it operates in a single business segment, which is a clinical-stage biopharmaceutical company developing differentiated therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high unmet need. Refer to Note 8 – Segmented Information for further information related to the Company’s segment. Grant Income Grant income is recognized at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred. Income Taxes The Company follows the provisions of ASC 740, which requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations and comprehensive loss. The Company recognizes interest and penalties related to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets. Share-based Compensation The Company accounts for all share-based payments and awards under the fair value method. The fair value of all share-based payments are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital. Compensation costs for share-based payments with graded vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards as they occur. The Company has granted share purchase option awards that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement of the performance criteria. The Company uses the Black-Scholes option valuation model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions, including the expected price volatility and expected life of each award. The Company uses the U.S. Treasury daily treasury yield curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are expected to be outstanding using the simplified method. Historically, the Company’s historical share option exercise experience did not provide sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management’s judgment. Changes in these assumptions can materially affect the fair value estimates. The purchase price of share-based compensation awards may be paid in cash or, if approved by the Company’s compensation committee (or in the case of warrants by the Board of Directors) in advance, “net settled” in shares of the Company’s common stock. In a net settlement of an share-based award, the Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued from the Company’s treasury. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date; Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities. At September 30, 2025 and 2024, the Company did not have any Level 2 or Level 3 assets or liabilities. Recently Adopted Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-07, “Segment Reporting: Improvements to Reportable Segment Disclosures.” This guidance requires disclosure of incremental segment information on an annual and interim basis, including disclosure of the title and position of the Chief Operating Decision Maker and requires that a public entity that has a single reportable segment to provide all the disclosures required by the amendments in ASU No. 2023-07. The Company adopted the new standard effective September 30, 2025, and for subsequent interim periods. Since ASU No. 2023-07 addresses only disclosures, the adoption of ASU No. 2023-07 did not have a significant impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes: Improvements to Income Tax Disclosures.” This guidance requires consistent categories and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures. In November 2024, the FASB issued ASU No. 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures. The amendments in ASU No. 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to the financial statements for certain categories of expenses that are included on the face of the financial statements. The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of this guidance on its disclosures.

Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Principles of Consolidation These consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (“Anavex Australia”), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have been eliminated.

Cash and equivalents The Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts, money market funds and certificates of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company’s investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The Company currently maintains the majority of its investments at one large well known financial institution. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000, under current regulations. At September 30, 2025 and 2024, substantially all of the Company’s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.

Research and Development Expenses Research and development costs are expensed as incurred. These expenses are comprised of the costs of the Company’s proprietary research and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including external research and development expenses incurred under arrangements with third parties such as contract research organizations (“CROs”), facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (“ASC”) 730, Research and Development, as these materials have no alternative future use outside of their intended use. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from actual costs. In addition, the Company incurs expenses in respect of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents and trademarks will ever be successfully commercialized. Due to these risks and uncertainties, the patent and trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.

Research and Development Incentive Income The Company is eligible to obtain certain research and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development tax incentive credit (the “Australia R&D credit”) through a program administered through the Australian Tax Office (the “ATO”) and AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science (“AusIndustry”). The Australia R&D credit program provides for a cash refund based on a percentage of eligible research and development activities undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&D credit program to receive the cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by AusIndustry pursuant to an advanced overseas finding application. The Australia R&D credit program is available to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate of 18.5% above the claimant’s company tax rate in Australia. The tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes (“ASC 740”), since the incentives are not linked to the Company’s taxable income and can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions. With respect to the Australia R&D credit, as there is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant by analogy to IAS20 Accounting for Government Grants and Disclosure of Government Assistance (“IAS 20”). The Company recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&D credit program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry, pursuant to an approved advanced overseas finding application. In addition, Anavex Australia and Anavex Canada incur Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance sheets.

License Fees The Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense or capitalized based on management’s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite regulatory approvals are obtained to make the product available for sale.

Basic and Diluted Loss per Share Basic income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. As of September 30, 2025, diluted loss per share excludes 14,971,583 potentially dilutive common shares (2024 - 15,047,754; 2023 – 14,271,780) related to outstanding options and warrants, as their effect was anti-dilutive.

14971583

15047754

14271780

Financial Instruments The book value of the Company’s financial instruments, consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Foreign Currency Translation The functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income in the period in which they occur. The Company has determined that the functional currency of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.

Segment and Geographic Reporting The Company determines and presents operating segments based on the information that is internally provided to the Company’s chief operating decision maker (“CODM”), its Chief Executive Officer, in accordance with ASC 280, Segment Reporting. The Company has determined that it operates in a single business segment, which is a clinical-stage biopharmaceutical company developing differentiated therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high unmet need. Refer to Note 8 – Segmented Information for further information related to the Company’s segment.

Grant Income Grant income is recognized at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.

Income Taxes The Company follows the provisions of ASC 740, which requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations and comprehensive loss. The Company recognizes interest and penalties related to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.

Share-based Compensation The Company accounts for all share-based payments and awards under the fair value method. The fair value of all share-based payments are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital. Compensation costs for share-based payments with graded vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards as they occur. The Company has granted share purchase option awards that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement of the performance criteria. The Company uses the Black-Scholes option valuation model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions, including the expected price volatility and expected life of each award. The Company uses the U.S. Treasury daily treasury yield curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are expected to be outstanding using the simplified method. Historically, the Company’s historical share option exercise experience did not provide sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management’s judgment. Changes in these assumptions can materially affect the fair value estimates. The purchase price of share-based compensation awards may be paid in cash or, if approved by the Company’s compensation committee (or in the case of warrants by the Board of Directors) in advance, “net settled” in shares of the Company’s common stock. In a net settlement of an share-based award, the Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued from the Company’s treasury.

Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date; Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities. At September 30, 2025 and 2024, the Company did not have any Level 2 or Level 3 assets or liabilities.

Recently Adopted Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-07, “Segment Reporting: Improvements to Reportable Segment Disclosures.” This guidance requires disclosure of incremental segment information on an annual and interim basis, including disclosure of the title and position of the Chief Operating Decision Maker and requires that a public entity that has a single reportable segment to provide all the disclosures required by the amendments in ASU No. 2023-07. The Company adopted the new standard effective September 30, 2025, and for subsequent interim periods. Since ASU No. 2023-07 addresses only disclosures, the adoption of ASU No. 2023-07 did not have a significant impact on the Company’s consolidated financial statements.

Recent Accounting Pronouncements In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes: Improvements to Income Tax Disclosures.” This guidance requires consistent categories and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures. In November 2024, the FASB issued ASU No. 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures. The amendments in ASU No. 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to the financial statements for certain categories of expenses that are included on the face of the financial statements. The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact of this guidance on its disclosures. Note 3 Accrued Liabilities The principal components of accrued liabilities consist of (in thousands): <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zEFXjdmOG7z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of principal components of accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20250930_zyqxLuwprtle" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20240930_znZa56PfFcAk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="7" style="font-weight: bold; text-align: center">September 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr> <tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_z91BpzDoygW5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">96</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">860</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,527</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">523</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">557</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pn3n3_z7ckRxVrVmq4" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,711</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,891</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--TotalAccruedLiabilities_iTI_pn3n3_zK1vlMEb0Dl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,892</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,835</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zEFXjdmOG7z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of principal components of accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20250930_zyqxLuwprtle" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20240930_znZa56PfFcAk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="7" style="font-weight: bold; text-align: center">September 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr> <tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_z91BpzDoygW5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">96</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">860</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,527</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">523</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">557</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pn3n3_z7ckRxVrVmq4" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,711</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,891</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--TotalAccruedLiabilities_iTI_pn3n3_zK1vlMEb0Dl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,892</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,835</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

96000 860000

1562000

1527000

523000 557000

1711000

1891000

3892000 4835000 Note 4 Other Income Grant income As of September 30, 2025, the Company had received a $<span id="xdx_905_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn3n3_dm_c20241001__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zPyrNJOyGEda" title="Research and development incentive income">1.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX®2-73 (blarcamesine) related to Parkinson’s disease. Of the total, $0.5 million was received during the year ended September 30, 2023 and $0.5 million was received during the year ended September 30, 2021. The grant income has been deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During the year ended September 30, 2025, the Company recognized $37,000 (2024: $75,000; 2023: $25,000) of this grant on its statements of operations within grant income. At September 30, 2025 an amount of $0.8 million (2024: $0.8 million) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its statements of operations as the related expenditures are incurred to offset the income. Research and development incentive income Research and development incentive income represents the income earned by Anavex Australia of the Australia R&D credit. This cash incentive is received by Anavex Australia, upon filing of a claim in connection with Anavex Australia’s annual income tax return. During the year ended September 30, 2025, the Company recorded research and development incentive income of $0.6 million (AUD <span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn3n3_dm_c20241001__20250930__srt--CurrencyAxis__currency--AUD_zDlBmhIXs56h" title="Research and development incentive income">1.0 million) (2024: $2.3 million (AUD <span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930__srt--CurrencyAxis__currency--AUD_zTiZVTCD76Ek" title="Research and development incentive income">3.5 million); 2023: $2.7 million (AUD <span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930__srt--CurrencyAxis__currency--AUD_zT5bn2jEk2bh" title="Research and development incentive income">4.1 million)) in respect of the Australia R&D credit for eligible research and development expenses incurred during the year. This amount is included within Other income (expense) on the consolidated statements of operations and comprehensive loss. At September 30, 2025, Incentive and tax receivables includes $0.7 million (AUD 1.1 million) (2024: $2.3 million (AUD 3.3 million)) relating to Australia R&D credits earned during the year that are expected to be reimbursed upon filing of the Company’s annual claim under this program. The Australia R&D credit program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible (ii) if the specific R&D activities are eligible and (iii) if the individual R&D expenditures have nexus to such R&D activities. The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant data available. Anavex Australia is able to continue to claim the R&D tax incentive for as long as it remains eligible and continues to incur eligible research and development expenditures. Although the Company believes that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right to review the Company’s qualifying programs and related expenditures for a period of four years. If such a review were to occur, the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company’s assessments and any related subsequent appeals, it could require adjustment to and repayment of current or previous years’ claims already received. Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess penalties and interest on any such adjustments. Currently, the Company’s tax incentive claims from 2020 to 2025 are open to potential review by the ATO. Additionally, the period open for review is indefinite if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future. 1000000 500000 500000 37000000 75000000 25000000 800000 800000

600000

1000000.0

2300000

3500000

2700000

4100000

700000

1100000

2300000

3300000

Note 5 Equity Offerings Common Stock Common shares are voting and are entitled to dividends as declared at the discretion of the Board of Directors. Preferred Stock The Company’s Board of Directors (the “Board”) has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series. 2025 Sales Agreement On July 25, 2025, the Company entered into a Sales Agreement (the “2025 Sales Agreement”) with TD Securities (USA) LLC (the “Sales Agent”). Pursuant to the 2025 Sales Agreement, the Company may offer and sell up to an aggregate offering price of $<span id="xdx_903_ecustom--ValueOfSharesObligatedToPurchase_pn3n3_dm_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgzVfdDcvavj" title="Value of shares obligated to purchase">150 million (the “Offering”) in shares of common stock from time to time through the Sales Agent. Upon delivery of a placement notice based on the Company’s instructions and subject to the terms and conditions of the 2025 Sales Agreement, the Sales Agent may sell shares of common stock by methods deemed to be an “at the market offering”, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to the Company’s prior written consent. The Company is not obligated to make any sales of shares under the 2025 Sales Agreement. The Company or the Sales Agent may suspend or terminate the Offering upon notice to the other party, subject to certain conditions. The Sales Agent will act as sales agent on a commercially reasonable efforts basis consistent its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of Nasdaq. The Company has agreed to pay the Sales Agent commissions for its services of up to 3.0% of the gross proceeds from the sale of shares of common stock pursuant to the Sales Agreement. The Company has also agreed to provide the Sales Agent with customary indemnification and contribution rights. During the year ended September 30, 2025, the Company issued 927,910 shares of common stock for net proceeds of $9.2 million pursuant to the 2025 Sales Agreement. 2023 Purchase Agreement On February 3, 2023, the Company entered into a $150.0 million purchase agreement (the “2023 Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pn3n3_dm_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zNTZOA9fzaY9" title="Value of shares obligated to purchase">150.0 million in value of its shares of common stock from time to time over a three-year period until February 3, 2026. In consideration for entering into the 2023 Purchase Agreement, the Company issued to Lincoln Park <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zQcYwUOS2Lod" title="Share issued for offering, shares">75,000 shares of common stock as a commitment fee (the “initial commitment shares”) and agreed to issue up to an additional <span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zU6fyfMArFzi" title="Pro rata basic number of shares obligated to purchase">75,000 shares pro rata, when and if, Lincoln Park purchased, at the Company’s discretion, the $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_dm_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zz4L6KMbsd98" title="Proceeds from issuance or sale of equity">150.0 million aggregate commitment. The Company determined the fair value of the initial commitment shares was $0.8 million with reference to the closing price of the Company’s shares on the Purchase Agreement date. In addition, the Company incurred third party expenses of $0.1 million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense on the statements of operations during the year ended September 30, 2023. During the year ended September 30, 2025, the Company did not issue any shares of common stock under the 2023 Purchase Agreement. During the year ended September 30, 2024, the Company issued to Lincoln Park an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zG4l7ZvjtNE3" title="Number of shares issued, shares">2,455,646 shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_zDEJXtBLySoe" title="Number of shares issued, shares">2,450,000 shares of common stock for an aggregate purchase price of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_dm_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zuy4NyY9D1N3" title="Number of shares issued, value">11.3 million and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zO3MTIC3nZj8" title="Number of shares issued, shares">5,646 commitment shares. During the year ended September 30, 2023, the Company issued to Lincoln Park an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zefqrGFq41vd" title="Number of shares issued, shares">3,288,943 shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_zRKoC3QKcy4b" title="Number of shares issued, shares">3,275,000 shares of common stock for aggregate proceeds of $<span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues2_pn5n6_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEchpl1UyS6c" title="Number of shares issued, value">27.9 million and <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zirlILwWijVk" title="Number of shares issued, shares">13,943 commitment shares. At September 30, 2025, there was an unused amount of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueOther_pn3n3_dm_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zxkT7KPRncse" title="Amount of shares remain available">110.8 million under the 2023 Purchase Agreement. The Company will need to file a prospectus supplement in order to access funds under the 2023 Purchase Agreement. Exercise of Stock Options During the year ended September 30, 2025, the Company issued 217,503 shares of common stock to the Company’s Chief Executive Officer upon a net exercise of an option to purchase <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zHCh2lYflJAh" title="Exercise option shares purchase">500,000 shares of common stock at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z0K8goYCYl5l" title="Common stock exercise price">0.92 per share. In connection with the exercise, the Company withheld <span id="xdx_901_ecustom--CommonStockConsiderationExerciseShares_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zptS1rPbLdAg" title="Common stock consideration exercise shares">47,745 shares of common stock as consideration of the exercise price of $0.46 million and <span id="xdx_904_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZ4qo5NmjuGa" title="Consideration shares issued">234,752 shares of common stock as consideration for the payment of $<span id="xdx_90E_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_dm_c20241001__20250930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zfJ8OqevFlq2" title="Consideration payment">2.3 million in connection with tax withholding obligations associated with the exercise. The number of shares withheld were based upon a market price of $9.63 per share as determined by reference to the average high and low sales price reported on the Nasdaq stock exchange on the date of exercise. During the year ended September 30, 2025, the Company issued 38,651 shares of common stock to a director of the Company upon a net exercise of an option to purchase 50,000 shares of common stock at an exercise price of $1.76 per share. The Company withheld 11,349 shares of common stock as consideration of the exercise price of $<span id="xdx_902_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_c20241001__20250930__srt--TitleOfIndividualAxis__srt--DirectorMember_zi3z3HaXphyc" title="Consideration payment">88,000. The number of shares withheld were based upon a market price of $7.75 per share as determined by reference to the average high and low sales price reported on the Nasdaq stock exchange on the date of exercise During the year ended September 30, 2025, the Company issued 42,452 shares of common stock to the Company’s Chief Executive Officer upon a net exercise of an option to purchase <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_z86Ta8DByNQ6" title="Exercise option shares purchase">187,500 shares of common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zprUIgjB3PRl" title="Common stock exercise price">5.04 per share. In connection with the exercise, the Company withheld <span id="xdx_904_ecustom--CommonStockConsiderationExerciseShares_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOffice1rMember_zUPfuIALfIug" title="Common stock consideration exercise shares">98,643 shares of common stock as consideration of the exercise price of $0.9 million and <span id="xdx_904_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pip0_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zTHUd0TFfjdk" title="Consideration shares issued">46,405 shares of common stock as consideration for the payment of $<span id="xdx_907_eus-gaap--OtherSignificantNoncashTransactionValueOfConsiderationGiven1_pn3n3_dm_c20241001__20250930__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficer1Member_zXKWeicBVcI9" title="Consideration payment">0.4 million in connection with tax withholding obligations associated with the exercise. The number of shares withheld were based upon a market price of $9.58 per share as determined by reference to the closing price reported on the Nasdaq stock exchange on the date of exercise. 150000000

927910

9200000

150000000.0

75000

150000000.0

800000 100000

2455646

2450000

11300000

5646

3288943

3275000

27900000

13943

110800000

217503

500000

0.92

47745

0.46

234752

2300000

9.63

38651

50000

1.76

11349000

88000000

7.75

42452

187500

5.04

98643

0.9

46405

400000

9.58

Note 6 Commitments and Contingencies Lease The Company leases office space under an operating lease with an initial term of 12 months or less. Under the terms of the office lease, the Company is required to pay its proportionate share of operating costs. The operating lease costs were as follows (in thousands): <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--LeaseCostTableTextBlock_pn3n3_zLGK3MGNJdu8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom"> <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">Schedule of operating lease costs</td><td style="font-weight: bold"> </td> <td colspan="3" id="xdx_49A_20241001__20250930_zIJOpFzaZD61" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" id="xdx_49E_20231001__20240930_zZipdRTLjkMb" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" id="xdx_491_20221001__20230930_z67COQZbK2se" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseCost_zWMuXvMMUw3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">134</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">125</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">118</td><td style="width: 1%; text-align: left"> </td></tr> </table> Employee 401(k) Benefit Plan The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees. The Company made matching contributions under the 401(k) plan as follows (in thousands): <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_ze32GXQdn995" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"> <tr style="vertical-align: bottom"> <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt">Schedule of contributions under the plan</td><td style="color: black; font-weight: bold"> </td> <td colspan="3" id="xdx_495_20241001__20250930_zOHLuBnpjGgk" style="color: black; font-weight: bold; text-align: center"> </td><td style="color: black; font-weight: bold"> </td> <td colspan="3" id="xdx_49C_20231001__20240930_zHvshI3hnLy" style="color: black; font-weight: bold; text-align: center"> </td><td style="color: black; font-weight: bold"> </td> <td colspan="3" id="xdx_49D_20221001__20230930_zjLfn9CR0Wtk" style="color: black; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="color: black; font-weight: bold"> </td> <td colspan="11" style="color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="color: black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2025</td><td style="color: black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr> <tr id="xdx_40C_eus-gaap--PensionContributions_z8DWIeNHh9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; color: black; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">255</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">279</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">232</td><td style="width: 1%; text-align: left"> </td></tr> </table> Litigation The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s consolidated financial statements. The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements. On March 13, 2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York and it named the Company and an officer of the Company as Defendants. The complaint was amended on July 12, 2024 (the “Initial Action”). The complaint alleged violations of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect to certain clinical trials for ANAVEX®2-73 related to Rett syndrome. This lawsuit was dismissed by the United States District Court for the Southern District of New York on June 18, 2025. The plaintiff filed a notice of appeal on July 17, 2025. Briefing on the appeal concluded October 30, 2025. No decision has been entered. No amount has been recorded in these consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur. On May 8, 2024, a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants. The Company believed that this lawsuit was also without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily dismissed this complaint subsequent to the filing of the motion to dismiss. On or about May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the Company’s Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding the same or similar allegations at issue in the purported class action lawsuit related to disclosures and statements made about certain clinical trials related to Rett syndrome. On January 22, 2025, pursuant to a stipulation of the parties, the Court entered an order staying this purported derivative lawsuit until the motion to dismiss filed by defendants in the Initial Action is decided by the U.S. District Court for the Southern District of New York. The stay has been extended through the appeal. No amount has been recorded in these consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur. On February 14, 2025, another derivative lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations was filed against the Company (as nominal defendant), an officer of the Company, and members of the Company’s Board of Directors in the Supreme Court for the State of New York, County of New York, by another purported shareholder. On August 18, 2025, pursuant to a stipulation of the parties, the Court entered an order staying this purported derivative lawsuit until the appeal in the Initial Action is resolved. No amount has been recorded in these consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur. We know of no other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries’ interest. Share Purchase Warrants At September 30, 2025 and 2024, the Company had 10,000 share purchase warrants outstanding exercisable at $12.00 per share until April 21, 2026. Stock–based Compensation Plan 2015 Stock Option Plan On September 18, 2015, the Company’s Board approved a 2015 Omnibus Incentive Plan (the “2015 Plan”), which provided for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company. The maximum number of our common shares reserved for issue under the plan was <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z4Q3gSc6tkfb" title="Maximum number of common shares reserved for future issuance">6,050,553 shares, subject to adjustment in the event of a change of the Company’s capitalization. 2019 Stock Option Plan On January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the “2019 Plan”), which provides for the grant of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. The maximum number of our common shares reserved for issue under the plan was <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20241001__20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zChJA0Sxc9G8" title="Additional shares of common stock available for issuance">6,000,000 shares, subject to adjustment in the event of a change of the Company’s capitalization. During the year ended September 30, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pip0_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zyqJszKauha9" title="Option granted">406,453 options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below). 2022 Stock Option Plan On March 25, 2022, the Board approved the 2022 Omnibus Incentive Plan (the “2022 Plan”). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022 Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20220324__20220325__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zeGOJAlloWq8" title="Additional shares of common stock available for issuance">10,000,000 additional shares of Common Stock will be available for issuance under the plan, in addition to the shares available under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan. The 2022 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s shares of common stock on the grant date. Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. On April 17, 2025, the Board approved an amendment to the 2022 Plan (the “Amendment”). The Amendment was approved by the stockholders on June 10, 2025. The Amendment increased the number of shares of common stock reserved for issuance under the 2022 Plan by 4,000,000 shares for a total of 14,000,000. In addition, the Amendment established a minimum vesting period of one year for all awards granted under the 2022 Plan and limited the discretion to accelerate the vesting of awards upon a separation from service, with limited exceptions permitted. Finally, the Amendment prohibited liberal share recycling provisions. At September 30, 2025, 6,504,829 options had been issued under the 2022 Plan and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_z3iQSmN4Y0sf" title="Option available issue">8,436,882 options were available for issue under the 2022 Plan. The following summarizes information about stock option activity during the years ended September 30, 2025: <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zMAuyzGA2ub8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of stock option activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="color: white"> </td> <td style="color: white; text-align: left"> </td><td style="color: white; text-align: right"> </td><td style="color: white; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price ($)</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value ($)</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value ($)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt">Outstanding, September 30, 2024</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrDrKVnujtdg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of options, Outstanding beginning balance">15,037,754</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ZDZFyqWmI6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance">6.80</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsE1B6uFOVd5" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance">5.12</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1errfXlh8Yg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance">15,825,791</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAYcb0woC0k3" style="text-align: right" title="Number of options, Granted">1,488,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMNxguD2E3j5" style="text-align: right" title="Weighted average exercise price, Granted">8.58</td><td style="text-align: left"> </td><td style="color: white"> </td> <td style="color: white; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znhJQVsdiI8d" style="text-align: right" title="Weighted average grant date fair value, Granted">6.22</td><td style="color: white; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zybc6fWFW7ha" style="text-align: right" title="Number of options, Expired">(100,100</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfJ264tHNym7" style="text-align: right" title="Weighted average exercise price, Expired">16.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKTyWPdQWJcf" style="text-align: right" title="Number of options, Exercised">(1,383,988</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsXbjubtAJjb" style="text-align: right" title="Weighted average exercise price, Exercised">3.21</td><td style="text-align: left"> </td><td style="color: white"> </td> <td style="color: white; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfcBnIF9bMaj" style="text-align: right" title="Weighted average grant date fair value, Exercised"> 1.31</td><td style="color: white; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzfG4883Xg2g" style="text-align: right" title="Aggregate intrinsic value, Exercised">9,324,901</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFBlpfLp5kQe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(80,583</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfjSLbhDqvtl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">4.56</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ObKFMoJrWc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">0.55</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z19ucprLcgS7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding ending balance">14,961,583</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9rYvQy4sud" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance">7.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1rKyhJroJkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Outstanding ending balance">5.46</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z344IAKZum9l" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance">39,715,608</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPQI44vUCf11" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable">10,418,213</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoSubcAxPJQk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">6.22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsFc6cCSWnW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Exercisable">4.83</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbEMxWQ89kt1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable">34,762,588</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following summarizes information about stock options at September 30, 2025 by a range of exercise prices: <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zZvFeODwATQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">Schedule of summarizes information about stock options</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Range of exercises prices</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of outstanding</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of vested</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">From</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">To</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(in years)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxYN7hHqR4B9" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Lower range limit">2.30</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsqM0silFxBa" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Upper range limit">5.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zhkFOTBe0x44" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of outstanding options">4,315,700</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsBDyLEeDv1g" title="Weighted average remaining contractual life">3.15</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zmX1s7evjBc3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price">3.02</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxNeCJnLt3Ek" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of vested options">4,220,283</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zWWJ8Ja45XEc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price options vested">2.99</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zXqfKH8v7tB4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">5.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ztKJ50TDZAaa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">7.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zwtchAcDnVy5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">3,299,536</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zOD4KFHqLWFc" title="Weighted average remaining contractual life">5.23</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zMXVApfwnbye" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">5.62</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z6QnwWX4Ditg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">2,325,162</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zZAVuBEYr4gh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">5.72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUht1UO2aex1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">7.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zfqeQDM5ew0f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">9.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2UPuVTMYFS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">4,372,347</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTKSmHCQIUel" title="Weighted average remaining contractual life">6.66</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zbO88lQNtoPj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">8.09</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z5M04ry9PRAj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">2,222,101</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2qn76qyieRk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">7.82</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_znVh8X6kNeCj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">9.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3RjfNfj6a07" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">13.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_ziNfLlIh6zNi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">1,609,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZiMFdT9M54l" title="Weighted average remaining contractual life">6.31</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zMJwqgNnrXte" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">10.29</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zlxWmYRpuc35" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">1,120,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zzv1vXIqLBue" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">10.37</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z1WTTJpPSKbb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">13.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zH4K4ZLjlZC8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">25.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z7on3N9dOCcc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">1,365,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT4jk8nQvG57" title="Weighted average remaining contractual life">5.91</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zktkXtOXgkH9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">18.33</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zY3g27ILay83" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">530,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBp15L52zgqg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">18.67</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z88YIicqOvj6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">14,961,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBaB9MhtDPrb" title="Weighted average remaining contractual life">5.22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBXUBkfD88Fb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">7.25</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNZ6TnWEEXM8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">10,418,213</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6okIJiIgxGk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">6.22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The weighted average per share fair value of options vested at September 30, 2025 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250930_zXe09v8Nrp0g" title="Weighted average grant date fair value of options vested">4.83 (2024: $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930_zDmfeLFZWZXg" title="Weighted average grant date fair value of options vested">4.34; 2023: $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930_zimoxsiShoF5" title="Weighted average grant date fair value of options vested">3.94). At September 30, 2025, the weighted average contractual life of options outstanding was <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930_zEqoepsiaxR1" title="Weighted average contractual life of options outstanding">5.22 years (2024: <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zE1fHsCVaO78" title="Weighted average contractual life of options outstanding">5.48 years; 2023: <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zOkLtOJoSRe2" title="Weighted average contractual life of options outstanding">6.0 years) and for options exercisable was <span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930_zpMC8suFkDw" title="Options exercisable">4.11 years (2024: <span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zyZwf0KNFeDh" title="Options exercisable">4.03 years; 2023: <span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zLZyD2LSSVWd" title="Options exercisable">4.75 years). The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Company’s stock for the options that were in-the-money at September 30, 2025. The Company recognized share-based compensation expense of $11.5 million during the year ended September 30, 2025 (2024: $9.4 million; 2023: $16.4 million) in connection with the issuance and vesting of stock options in exchange for services. These amounts have been included in general and administrative expenses and research and development expenses on the Company’s consolidated statements of operations as follows (in thousands): <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zy1ul9YLEJZ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Schedule of general and administrative expenses and research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__srt--ConsolidatedEntitiesAxis__custom--GeneralAndAdministrativeExpensesMember_zRiL3I5nChFd" style="width: 11%; text-align: right" title="Total share based compensation">4,536</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__srt--ConsolidatedEntitiesAxis__custom--GeneralAndAdministrativeExpensesMember_zpDN9teUuRi4" style="width: 11%; text-align: right" title="Total share based compensation">3,625</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__srt--ConsolidatedEntitiesAxis__custom--GeneralAndAdministrativeExpensesMember_zIqsCboZQ0r4" style="width: 11%; text-align: right" title="Total share based compensation">5,558</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__srt--ConsolidatedEntitiesAxis__custom--ResearchAndDevelopmentExpensesMember_z4rdPH4Is4Zb" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">7,013</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__srt--ConsolidatedEntitiesAxis__custom--ResearchAndDevelopmentExpensesMember_zQ4r78XYGHp8" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">5,813</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__srt--ConsolidatedEntitiesAxis__custom--ResearchAndDevelopmentExpensesMember_zdd5iSA0TnDb" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">10,812</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930_zI3bl7GkOB54" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">11,549</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zjWKBnIfnP51" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">9,438</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zViBeqdRp5qj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">16,370</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> An amount of approximately $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_dm_c20250930_zwTvGhP3rrrc" title="Remaining stock based compensation">6.3 million in share-based compensation is expected to be recorded over the remaining term of such options and warrants through fiscal 2029. The fair value of each option and warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions: <table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zsEUpKdNDZFl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of weighted average assumptions for fair value of each option award</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3.98</td><td style="width: 1%; text-align: left">%</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">4.28</td><td style="width: 1%; text-align: left">%</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3.70</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.78</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86.49</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84.81</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85.13</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> </table> The fair value of stock compensation charges recognized during the years ended September 30, 2025, 2024 and 2023 was determined with reference to the quoted market price of the Company’s shares on the grant date.

P12M

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--LeaseCostTableTextBlock_pn3n3_zLGK3MGNJdu8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom"> <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-size: 10pt; text-align: center; text-indent: -10pt">Schedule of operating lease costs</td><td style="font-weight: bold"> </td> <td colspan="3" id="xdx_49A_20241001__20250930_zIJOpFzaZD61" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" id="xdx_49E_20231001__20240930_zZipdRTLjkMb" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" id="xdx_491_20221001__20230930_z67COQZbK2se" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseCost_zWMuXvMMUw3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">134</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">125</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">118</td><td style="width: 1%; text-align: left"> </td></tr> </table>

134000

125000

118000

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_ze32GXQdn995" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"> <tr style="vertical-align: bottom"> <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt">Schedule of contributions under the plan</td><td style="color: black; font-weight: bold"> </td> <td colspan="3" id="xdx_495_20241001__20250930_zOHLuBnpjGgk" style="color: black; font-weight: bold; text-align: center"> </td><td style="color: black; font-weight: bold"> </td> <td colspan="3" id="xdx_49C_20231001__20240930_zHvshI3hnLy" style="color: black; font-weight: bold; text-align: center"> </td><td style="color: black; font-weight: bold"> </td> <td colspan="3" id="xdx_49D_20221001__20230930_zjLfn9CR0Wtk" style="color: black; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="color: black; font-weight: bold"> </td> <td colspan="11" style="color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="color: black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2025</td><td style="color: black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr> <tr id="xdx_40C_eus-gaap--PensionContributions_z8DWIeNHh9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; color: black; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">255</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">279</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">232</td><td style="width: 1%; text-align: left"> </td></tr> </table>

255000

279000

232000

10000

12.00

6050553

6000000

406453

10000000

14000000

6504829

8436882

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zMAuyzGA2ub8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of stock option activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="color: white"> </td> <td style="color: white; text-align: left"> </td><td style="color: white; text-align: right"> </td><td style="color: white; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price ($)</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value ($)</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value ($)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt">Outstanding, September 30, 2024</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrDrKVnujtdg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of options, Outstanding beginning balance">15,037,754</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3ZDZFyqWmI6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance">6.80</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsE1B6uFOVd5" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance">5.12</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1errfXlh8Yg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance">15,825,791</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAYcb0woC0k3" style="text-align: right" title="Number of options, Granted">1,488,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMNxguD2E3j5" style="text-align: right" title="Weighted average exercise price, Granted">8.58</td><td style="text-align: left"> </td><td style="color: white"> </td> <td style="color: white; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGranted_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znhJQVsdiI8d" style="text-align: right" title="Weighted average grant date fair value, Granted">6.22</td><td style="color: white; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zybc6fWFW7ha" style="text-align: right" title="Number of options, Expired">(100,100</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfJ264tHNym7" style="text-align: right" title="Weighted average exercise price, Expired">16.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKTyWPdQWJcf" style="text-align: right" title="Number of options, Exercised">(1,383,988</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsXbjubtAJjb" style="text-align: right" title="Weighted average exercise price, Exercised">3.21</td><td style="text-align: left"> </td><td style="color: white"> </td> <td style="color: white; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercised_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfcBnIF9bMaj" style="text-align: right" title="Weighted average grant date fair value, Exercised"> 1.31</td><td style="color: white; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzfG4883Xg2g" style="text-align: right" title="Aggregate intrinsic value, Exercised">9,324,901</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFBlpfLp5kQe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(80,583</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfjSLbhDqvtl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">4.56</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageForfeited_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ObKFMoJrWc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">0.55</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z19ucprLcgS7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding ending balance">14,961,583</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9rYvQy4sud" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance">7.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1rKyhJroJkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Outstanding ending balance">5.46</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z344IAKZum9l" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance">39,715,608</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPQI44vUCf11" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable">10,418,213</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoSubcAxPJQk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">6.22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsFc6cCSWnW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Exercisable">4.83</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbEMxWQ89kt1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable">34,762,588</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

15037754

6.80

5.12

15825791

1488500

8.58

6.22

100100

16.23

1383988

3.21

1.31

9324901

80583

4.56

0.55

14961583

7.25

5.46

39715608

10418213

6.22

4.83

34762588

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zZvFeODwATQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">Schedule of summarizes information about stock options</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Range of exercises prices</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of outstanding</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Number of vested</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">From</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">To</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(in years)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxYN7hHqR4B9" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Lower range limit">2.30</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsqM0silFxBa" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Range of exercise prices, Upper range limit">5.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zhkFOTBe0x44" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of outstanding options">4,315,700</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zsBDyLEeDv1g" title="Weighted average remaining contractual life">3.15</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zmX1s7evjBc3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price">3.02</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxNeCJnLt3Ek" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of vested options">4,220,283</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zWWJ8Ja45XEc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price options vested">2.99</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zXqfKH8v7tB4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">5.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ztKJ50TDZAaa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">7.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zwtchAcDnVy5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">3,299,536</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zOD4KFHqLWFc" title="Weighted average remaining contractual life">5.23</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zMXVApfwnbye" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">5.62</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z6QnwWX4Ditg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">2,325,162</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zZAVuBEYr4gh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">5.72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUht1UO2aex1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">7.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zfqeQDM5ew0f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">9.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2UPuVTMYFS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">4,372,347</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTKSmHCQIUel" title="Weighted average remaining contractual life">6.66</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zbO88lQNtoPj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">8.09</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z5M04ry9PRAj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">2,222,101</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2qn76qyieRk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">7.82</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_znVh8X6kNeCj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">9.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3RjfNfj6a07" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">13.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_ziNfLlIh6zNi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">1,609,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZiMFdT9M54l" title="Weighted average remaining contractual life">6.31</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zMJwqgNnrXte" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">10.29</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zlxWmYRpuc35" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">1,120,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zzv1vXIqLBue" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">10.37</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z1WTTJpPSKbb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Lower range limit">13.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zH4K4ZLjlZC8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of exercise prices, Upper range limit">25.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z7on3N9dOCcc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">1,365,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zT4jk8nQvG57" title="Weighted average remaining contractual life">5.91</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zktkXtOXgkH9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">18.33</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zY3g27ILay83" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">530,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBp15L52zgqg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">18.67</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z88YIicqOvj6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding options">14,961,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBaB9MhtDPrb" title="Weighted average remaining contractual life">5.22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBXUBkfD88Fb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price">7.25</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNZ6TnWEEXM8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of vested options">10,418,213</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6okIJiIgxGk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price options vested">6.22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2.30

5.00

4315700

P3Y1M24D

3.02

4220283

2.99

5.01

7.00

3299536

P5Y2M23D

5.62

2325162

5.72

7.01

9.00

4372347

P6Y7M28D

8.09

2222101

7.82

9.01

13.00

1609000

P6Y3M21D

10.29

1120667

10.37

13.01

25.00

1365000

P5Y10M28D

18.33

530000

18.67

14961583

P5Y2M19D

7.25

10418213

6.22

4.83

4.34

3.94

P5Y2M19D

P5Y5M23D

P6Y

P4Y1M9D

P4Y10D

P4Y9M

11500000

9400000

16400000

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zy1ul9YLEJZ4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Schedule of general and administrative expenses and research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="11" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__srt--ConsolidatedEntitiesAxis__custom--GeneralAndAdministrativeExpensesMember_zRiL3I5nChFd" style="width: 11%; text-align: right" title="Total share based compensation">4,536</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__srt--ConsolidatedEntitiesAxis__custom--GeneralAndAdministrativeExpensesMember_zpDN9teUuRi4" style="width: 11%; text-align: right" title="Total share based compensation">3,625</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__srt--ConsolidatedEntitiesAxis__custom--GeneralAndAdministrativeExpensesMember_zIqsCboZQ0r4" style="width: 11%; text-align: right" title="Total share based compensation">5,558</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930__srt--ConsolidatedEntitiesAxis__custom--ResearchAndDevelopmentExpensesMember_z4rdPH4Is4Zb" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">7,013</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__srt--ConsolidatedEntitiesAxis__custom--ResearchAndDevelopmentExpensesMember_zQ4r78XYGHp8" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">5,813</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__srt--ConsolidatedEntitiesAxis__custom--ResearchAndDevelopmentExpensesMember_zdd5iSA0TnDb" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">10,812</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250930_zI3bl7GkOB54" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">11,549</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zjWKBnIfnP51" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">9,438</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zViBeqdRp5qj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">16,370</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

4536000

3625000

5558000

7013000

5813000

10812000

11549000

9438000

16370000

6300000

<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zsEUpKdNDZFl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of weighted average assumptions for fair value of each option award</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3.98</td><td style="width: 1%; text-align: left">%</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">4.28</td><td style="width: 1%; text-align: left">%</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">3.70</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.78</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86.49</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84.81</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85.13</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> </table>

0.0398

0.0428

0.0370

P5Y6M25D

P5Y9M10D

P5Y7M20D

0.8649

0.8481

0.8513

0.0000

Note 7 Income Taxes The Company’s U.S. and foreign losses before income taxes are set forth below (in thousands): <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zJJSU3hcizE5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt">Schedule of loss before income taxes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20241001__20250930_z5MJb7OW8u69" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20231001__20240930_zFTtjaLIsDAh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20221001_20230930" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">United States</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(44,500</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(39,195</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(41,198</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,877</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,807</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,300</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(46,377</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(43,002</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(47,498</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> During the years ended September 30, 2025, 2024 and 2023, there were no current or deferred income tax provisions (benefits) for any U.S. federal, state & local, and foreign jurisdictions. The components of net deferred income tax assets as of September 30, 2025 and 2024 are as follows (in thousands): <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_z6GPFZ33krw8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of components of net deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20250930_zOY5k9iTWpFk" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20240930_zjQgJ3N6VP5j" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">54,752</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">48,134</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development tax credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,203</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,185</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,091</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development capitalization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,737</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,104</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Unpaid charges</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,843</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,197</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">946</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">758</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zOVd3Vxooh6e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(259</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(254</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zYf0Q9J5VkZ4" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance of deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(108,492</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(92,233</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements for the years ended September 30, 2025, 2024 and 2023 is as follows (in thousands): <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_z4dOHPfPkGL9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of reconciliation of income tax expense</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20241001__20250930_zHrqqR1Sedf8" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20231001__20240930_z8d0FFMP0se1" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20221001__20230930_znWxur4eJxqc" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Income tax benefit at statutory federal rate</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,739</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,975</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign income taxed at other rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(61</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,219</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(601</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to GILTI inclusion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">165</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(276</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">273</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development credits, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(941</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(860</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(37</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">State and local taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,672</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,821</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,122</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustment to true up to prior years’ tax provision</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,128</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">206</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance_zahCpujyiQi2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in valuation allowances</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,259</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15,186</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,098</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income tax expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of September 30, 2025, the Company had U.S. federal net operating loss carryforwards of approximately $148.8 million (2024: $128.5 million) of which $37.7 million will begin to expire in 2026 and $111.2 million can be carried forward indefinitely, state and local net operating loss carryforwards of approximately $ 19.1 million (2024: $16.9 million) which will begin to expire in 2036, and Research and Development tax credits of approximately $5.3 million (2024: $4.3 million) which will begin to expire in 2029. The calculation of the Research and Development tax credits, by their nature, involve estimates and subjectivity. If examined by the U.S. federal and state tax authorities, it is possible that some portion of these credit carryforwards would be disputed by the tax authorities. The Company had approximately $17.1 million (approximately AU$<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_pn5n6_c20250930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_z4k1lkTZXCJh" title="Operating loss carryforwards">25.9 million) (2024: $16.6 million (approximately AU$<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_pn5n6_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_znwFH72WmEX9" title="Operating loss carryforwards">23.9 million)) of net operating loss carryforwards in Australia, which have an indefinite life, available to offset future taxable income in those jurisdictions. The Company evaluates its valuation allowance requirements based on available evidence. When circumstances change, and this causes a change in management’s judgment about the recoverability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income. Because management of the Company does not currently believe that it is more likely than not that the Company will receive the benefit of these assets, a full valuation allowance has been established at September 30, 2025 and 2024. During the year ended September 30, 2025, the valuation allowance increased by $16.3 million (2024: $15.2 million; 2023: $14.1 million). The Tax Cuts and Jobs Act of 2017 (TCJA) has modified the treatment of IRC 174 expenses related to research and development for tax years beginning after December 31, 2021. Under the TCJA, the Company must capitalize the expenditures related to research and development activities and amortize them over 5 years for U.S. activities and over 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of research and development costs in accordance with IRC 174 has resulted in a net deferred tax assets at September 30, 2025 of $20.7 million (2024: $15.1 million). On July 4, 2025, the United States President signed into law the One Big Beautiful Bill Act (“OBBBA”), a budget reconciliation package that changes many key provisions of the U.S. federal income tax code, including extensions of various expiring provisions from the TCJA. The new legislation, which will be effective for the Company beginning in fiscal 2026, will now allow for more tax-payer favorable treatment of domestic research and development expenditures for US income tax purposes. Uncertain Tax Positions The Company files income tax returns in the U.S. federal jurisdiction and various state and local and foreign jurisdictions. The Company’s tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire. The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2005. Under the provisions of the Internal Revenue Code, the net operating loss (“NOL”) carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may become subject to an annual limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over a three-year period, as well as similar state tax provisions. The Company conducts a Section 382 study annually and has reduced its federal NOLs by $12.1 million and its Research and Development tax credit carryforwards by $0.8 million, which are the amount of tax assets that will expire unutilized pursuant to Section 382. Subsequent ownership changes in future years could trigger additional limitations of the Company’s NOLs. During the year ended September 30, 2025, the Company determined that there were no changes in ownership pursuant to Section 382. As of September 30, 2025, the Company did not provide any foreign withholding taxes related to its foreign subsidiaries’ undistributed earnings, as such earnings have been retained and are intended to be indefinitely reinvested to fund ongoing operations of the foreign subsidiaries. It is not practicable to estimate the amount of taxes that would be payable upon remittance of these earnings, because such tax, if any, is dependent upon circumstances existing if and when remittance occur. As of September 30, 2025 and 2024, the Company had determined that no liabilities for uncertain tax positions, interest or penalties were required to be recorded.

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zJJSU3hcizE5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt">Schedule of loss before income taxes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20241001__20250930_z5MJb7OW8u69" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20231001__20240930_zFTtjaLIsDAh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20221001_20230930" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">United States</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(44,500</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(39,195</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(41,198</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,877</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,807</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,300</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(46,377</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(43,002</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(47,498</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

-44500000

-39195000

-41198000

-1877000

-3807000

-6300000

-46377000

-43002000

-47498000

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_z6GPFZ33krw8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; display: none; text-align: left; text-indent: -10pt">Schedule of components of net deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20250930_zOY5k9iTWpFk" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20240930_zjQgJ3N6VP5j" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">54,752</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">48,134</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development tax credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,203</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,185</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,091</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development capitalization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,737</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,104</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Unpaid charges</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,843</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,197</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">946</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">758</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zOVd3Vxooh6e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(259</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(254</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zYf0Q9J5VkZ4" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance of deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(108,492</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(92,233</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

54752000

48134000

5288000

4203000

23185000

21091000

20737000 15104000 3843000 3197000

946000

758000

259000 254000

108492000

92233000

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_z4dOHPfPkGL9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of reconciliation of income tax expense</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20241001__20250930_zHrqqR1Sedf8" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20231001__20240930_z8d0FFMP0se1" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20221001__20230930_znWxur4eJxqc" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Income tax benefit at statutory federal rate</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,739</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(9,975</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign income taxed at other rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(61</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,219</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(601</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to GILTI inclusion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">165</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(276</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">273</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development credits, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(941</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(860</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(37</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">State and local taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,672</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,821</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,122</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustment to true up to prior years’ tax provision</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,128</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">206</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--IncomeTaxReconciliationChangeInTaxAssetsValuationAllowance_zahCpujyiQi2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in valuation allowances</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,259</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15,186</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,098</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income tax expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

-9739000

-9030000

-9975000

-61000

-1219000 -10000 -601000

165000

130000

-276000

273000

-941000 -860000 -37000

-4672000

-3821000

-4122000

182000

-1128000

206000

16259000 15186000 14098000

7000

148800000

128500000

$37.7

19100000

16900000

2036

5300000

4300000

2029

17100000

25900000

16600000

23900000

16300000

15200000

14100000

20700000

15100000

12100000

800000

Note 8 Segmented Information Operating segments are defined as components of an entity for which separate financial information is available and regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources and assess performance. The Company’s CODM is the Chief Executive Officer. The Company has determined that it operates in a single operating segment, which consists of the development of clinical and preclinical product candidates focused on advancing novel therapeutics for CNS diseases and disorders, and related administrative activities. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM evaluates performance and allocates resources based on consolidated net loss, as presented in the Company’s consolidated statement of operations, and monitors forecast-to-actual variances for significant expense categories given their direct relationship to cash burn. The CODM also reviews the consolidated balance sheet to assess liquidity, funding capacity, and segment assets, which are reported as total consolidated assets. The CODM receives and reviews financial information on a consolidated basis and does not assess performance or allocate resources based on geographic regions. In addition, management does not internally organize or evaluate operating results by geography. Accordingly, management has determined that it is not required to present financial information disaggregated by geographic region under ASC 280. The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended September 30, 2025, 2024 and 2023 (in thousands): <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_pn3n3_zVIDCKo5nnSl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segmented Information (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Schedule of summarizes the significant expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20241001__20250930_zLHHUDIGsfxd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20231001__20240930_zKk7pL1wdZwe" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20221001__20230930_zMYAJn06VFw8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; width: 46%; text-align: left; text-indent: -10pt">Preclinical studies</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zFrZBm3FoeY9" style="width: 11%; text-align: right" title="Research and development costs">543</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zxp07xxy7yY7" style="width: 11%; text-align: right" title="Research and development costs">663</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zH9KDDhEzkph" style="width: 11%; text-align: right" title="Research and development costs">627</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Clinical trials</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_z1WONuLox7we" style="text-align: right" title="Research and development costs">15,805</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zuj3PHG4gT9a" style="text-align: right" title="Research and development costs">21,301</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zcUamCUFHlx8" style="text-align: right" title="Research and development costs">21,873</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Personnel costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_z2yP8sByQ5me" style="text-align: right" title="Research and development costs">13,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpO21lKV8dJ5" style="text-align: right" title="Research and development costs">13,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zQXUpJcSUJy2" style="text-align: right" title="Research and development costs">10,264</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash share-based compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z60xdm80O0He" style="text-align: right" title="Research and development costs">7,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z2I3TxlZGWl2" style="text-align: right" title="Research and development costs">5,813</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zFJDZrcFbA51" style="text-align: right" title="Research and development costs">10,812</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Other research and development costs(a)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zZTM1o5KWTAl" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">765</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zY2z0BJ6cNu" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">385</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zPV5eE24LOyd" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">141</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total research and development costs</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930_znLAEUCsjnY4" style="font-weight: bold; text-align: right" title="Research and development costs">37,592</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930_zgxBsosS3X9f" style="font-weight: bold; text-align: right" title="Research and development costs">41,838</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_988_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930_zuC4GxaJ0iW2" style="font-weight: bold; text-align: right" title="Research and development costs">43,717</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">General and administrative costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Personnel costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zh6aOjZq8sT4" style="text-align: right" title="General and administrative costs">2,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpYJz6yuFcz" style="text-align: right" title="General and administrative costs">2,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zRa7H2ZF3xv9" style="text-align: right" title="General and administrative costs">2,527</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash share-based compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zuYd8YPkHrFd" style="text-align: right" title="General and administrative costs">4,536</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z97W6Cm3eqO" style="text-align: right" title="General and administrative costs">3,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z05ZWu0DGffg" style="text-align: right" title="General and administrative costs">5,558</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Other general and administrative costs(b)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zmqi0fztDEVc" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">6,992</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_z1zIttFFD8tg" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">5,237</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zWYlj8jzeV3k" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">3,961</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total general and administrative costs</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930_z84cBtzE4JTa" style="font-weight: bold; text-align: right" title="General and administrative costs">13,816</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930_zRTSScKRdqce" style="font-weight: bold; text-align: right" title="General and administrative costs">11,039</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930_zMzJBfRDgPl9" style="font-weight: bold; text-align: right" title="General and administrative costs">12,046</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OtherIncome_c20241001__20250930_zSQrsMX0gtDl" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">5,031</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--OtherIncome_c20231001__20240930_zBzEhImJe7Bb" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">9,875</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OtherIncome_c20221001__20230930_z7gQovPJrPY7" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">8,258</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20241001__20250930_zHoQRnoi8oKd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(46,377</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_c20231001__20240930_zBcrRhrJpkXd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(43,002</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_c20221001__20230930_zUh6s7Tme0V" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(47,505</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">(a)</td> <td style="text-align: justify">Other research and development costs include, but are not limited to, publications, sponsorships, membership fees, scientific conferences, and medical affairs strategy and branding.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">(b)</td> <td style="text-align: justify">Other general and administrative expenses include, but are not limited to, office rent, public company reporting requirements including professional fees, insurance, and other general operating expenses not otherwise included in research and development expenses.</td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_pn3n3_zVIDCKo5nnSl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segmented Information (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Schedule of summarizes the significant expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20241001__20250930_zLHHUDIGsfxd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20231001__20240930_zKk7pL1wdZwe" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20221001__20230930_zMYAJn06VFw8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; width: 46%; text-align: left; text-indent: -10pt">Preclinical studies</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zFrZBm3FoeY9" style="width: 11%; text-align: right" title="Research and development costs">543</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zxp07xxy7yY7" style="width: 11%; text-align: right" title="Research and development costs">663</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PreclinicalStudiesMember_zH9KDDhEzkph" style="width: 11%; text-align: right" title="Research and development costs">627</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Clinical trials</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_z1WONuLox7we" style="text-align: right" title="Research and development costs">15,805</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zuj3PHG4gT9a" style="text-align: right" title="Research and development costs">21,301</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--ClinicalTrialsMember_zcUamCUFHlx8" style="text-align: right" title="Research and development costs">21,873</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Personnel costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_z2yP8sByQ5me" style="text-align: right" title="Research and development costs">13,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpO21lKV8dJ5" style="text-align: right" title="Research and development costs">13,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zQXUpJcSUJy2" style="text-align: right" title="Research and development costs">10,264</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash share-based compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z60xdm80O0He" style="text-align: right" title="Research and development costs">7,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z2I3TxlZGWl2" style="text-align: right" title="Research and development costs">5,813</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zFJDZrcFbA51" style="text-align: right" title="Research and development costs">10,812</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Other research and development costs(a)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zZTM1o5KWTAl" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">765</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zY2z0BJ6cNu" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">385</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zPV5eE24LOyd" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development costs">141</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total research and development costs</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20241001__20250930_znLAEUCsjnY4" style="font-weight: bold; text-align: right" title="Research and development costs">37,592</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20231001__20240930_zgxBsosS3X9f" style="font-weight: bold; text-align: right" title="Research and development costs">41,838</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_988_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20221001__20230930_zuC4GxaJ0iW2" style="font-weight: bold; text-align: right" title="Research and development costs">43,717</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">General and administrative costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Personnel costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zh6aOjZq8sT4" style="text-align: right" title="General and administrative costs">2,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zpYJz6yuFcz" style="text-align: right" title="General and administrative costs">2,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--PersonnelCostsMember_zRa7H2ZF3xv9" style="text-align: right" title="General and administrative costs">2,527</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash share-based compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_zuYd8YPkHrFd" style="text-align: right" title="General and administrative costs">4,536</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z97W6Cm3eqO" style="text-align: right" title="General and administrative costs">3,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--NonCashShareBasedCompensationMember_z05ZWu0DGffg" style="text-align: right" title="General and administrative costs">5,558</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Other general and administrative costs(b)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zmqi0fztDEVc" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">6,992</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_z1zIttFFD8tg" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">5,237</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--OtherResearchAndDevelopmentCostsMember_zWYlj8jzeV3k" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative costs">3,961</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total general and administrative costs</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--SellingGeneralAndAdministrativeExpense_c20241001__20250930_z84cBtzE4JTa" style="font-weight: bold; text-align: right" title="General and administrative costs">13,816</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20231001__20240930_zRTSScKRdqce" style="font-weight: bold; text-align: right" title="General and administrative costs">11,039</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20221001__20230930_zMzJBfRDgPl9" style="font-weight: bold; text-align: right" title="General and administrative costs">12,046</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OtherIncome_c20241001__20250930_zSQrsMX0gtDl" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">5,031</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--OtherIncome_c20231001__20240930_zBzEhImJe7Bb" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">9,875</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OtherIncome_c20221001__20230930_z7gQovPJrPY7" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">8,258</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20241001__20250930_zHoQRnoi8oKd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(46,377</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_c20231001__20240930_zBcrRhrJpkXd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(43,002</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_c20221001__20230930_zUh6s7Tme0V" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net Loss">(47,505</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">(a)</td> <td style="text-align: justify">Other research and development costs include, but are not limited to, publications, sponsorships, membership fees, scientific conferences, and medical affairs strategy and branding.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">(b)</td> <td style="text-align: justify">Other general and administrative expenses include, but are not limited to, office rent, public company reporting requirements including professional fees, insurance, and other general operating expenses not otherwise included in research and development expenses.</td></tr> </table>

543000

663000

627000

15805000

21301000

21873000

13466000

13676000

10264000

7013000

5813000

10812000

765000

385000

141000

37592000

41838000

43717000

2288000

2177000

2527000

4536000

3625000

5558000

6992000

5237000

3961000

13816000

11039000

12046000

5031000

9875000

8258000

-46377000

-43002000

-47505000

Note 9 Subsequent Events The Company evaluates subsequent events occurring between the most recent balance sheet date and the date the financial statements are available to be issued in order to determine whether the subsequent events are to be recorded and/or disclosed in the Company’s financial statements and footnotes. The financial statements are considered to be available to be issued at the time they are filed with the Securities and Exchange Commission (SEC). There were no subsequent events or transactions that required recognition or disclosure in the consolidated financial statements.